Ultime notizie per Vaccinex (NASDAQ:VCNX) Azioni

Vaccinex

Vaccinex Inc is pioneering a differentiated approach to treating cancer and slowly progressive neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D). The company's lead drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that it believes prevents immune infiltration into tumors and triggers inflammation in chronic diseases of the brain. Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer's Disease, with ongoing exploration of potential Phase 3 development in Huntington's disease. The firm has also developed a proprietary drug discovery platform, ActivMAb.

Vaccinex Inc

Barclays analyst Alex Scott maintains Sun Life Financial (TSX:<a class="ticker" href="https://www.benzinga.com/stock/SLF#TSX">SLF</a>) with a Equal-Weight and raises the price target from C$76 to C$79.

News

Price Target

Analyst Ratings

TSX:SLF

Barclays Maintains Equal-Weight on Sun Life Financial, Raises Price Target to C$79

Bionomics Ltd &#8211; ADR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNOX#NASDAQ">BNOX</a>) shares are trading higher by 177% to 53 cents Tuesday morning after the company announced it <a href="https://www.benzinga.com/pressreleases/24/11/g41727839/bionomics-receives-milestone-payment-of-aus-1m-from-carina-biotech-for-bnc101-partnered-legacy-onc">received a milestone payment</a> of AUD$1 million from Carina Biotech related to their partnered oncology program, BNC101.
What To Know: This payment aligns with their 2020 exclusive license agreement for BNC101, a monoclonal antibody targeting LGR5, a cancer stem cell antigen. 
Carina Biotech is developing an LGR5-targeted CAR-T therapy, CNA3103, for metastatic colorectal cancer, and Bionomics could earn up to AUD$118 million in further development, regulatory and commercial milestone payments if the therapy is fully developed and marketed.
Additionally, Bionomics is set to earn royalties on net sales and may receive a share of sublicensing revenue. Bionomics' CEO highlighted this payment as a testament to their research strength and noted the progress of their strategic partnership with Merck for an Alzheimer&#8217;s therapy, which could soon yield additional milestone payments.
Read Also: <a href="https://www.benzinga.com/news/earnings/24/11/41740288/us-stocks-set-for-cautious-start-as-investors-brace-for-volatility-on-election-day-expert-points-to">US Stocks Set For Cautious Start As Investors Brace For Volatility On Election Day: Expert Points To &#8216;Pretty Well Overall&#8217; Historical Performance</a>
<h2 class="wp-block-heading">How To Buy BNOX Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Bionomics&#8217; case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, BNOX has a 52-week high of $2.84 and a 52-week low of $0.18.

BNOX

Why Bionomics (BNOX) Stock Is Up 100% Today

REQORSA Modulates In Vivo Immune Responses Against Cancers
AUSTIN, Texas, Nov. 5, 2024 /PRNewswire/ -- <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4294293-1&amp;h=152405195&amp;u=https%3A%2F%2Fwww.genprex.com%2F&amp;a=Genprex%2C+Inc.">Genprex, Inc.</a> ("Genprex" or the "Company") (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gnpx#NASDAQ">GNPX</a>), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators at Meharry Medical College will present a poster detailing positive preclinical data from a study of the Company's lead drug candidate, Reqorsa&#xAE; Gene Therapy (quaratusugene ozeplasmid)&nbsp;evaluating TUSC2's role in modulating immune responses in cancer. The poster will be presented at the 39th Annual Society for Immunotherapy of Cancer Meeting being held November 6-10, 2024 in Houston, Texas.

Biotech

Penny Stocks

General

GNPX

Genprex Collaborators Present Preclinical Data On Reqorsa Gene Therapy At The Society For Immunotherapy Of Cancer 2024 Annual Meeting; REQORSA Modulates In Vivo Immune Responses Against Cancers

Brinker International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EAT#NYSE">EAT</a>) has outperformed the market over the past 5 years by 5.75% on an annualized basis producing an average annual return of 18.82%. Currently, Brinker International has a market capitalization of $4.85 billion. 
Buying $1000 In EAT: If an investor had bought $1000 of EAT stock 5 years ago, it would be worth $2,342.45 today based on a price of $108.40 for EAT at the time of writing.
<h3>Brinker International's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730817033_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

$1000 Invested In This Stock 5 Years Ago Would Be Worth $2,300 Today

CRKN

Crown Suspends Equity Line of Credit Agreement With Liqueous LP

Union Pacific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNP#NYSE">UNP</a>) has outperformed the market over the past 15 years by 2.58% on an annualized basis producing an average annual return of 14.16%. Currently, Union Pacific has a market capitalization of $139.38 billion. 
Buying $100 In UNP: If an investor had bought $100 of UNP stock 15 years ago, it would be worth $740.21 today based on a price of $229.91 for UNP at the time of writing.
<h3>Union Pacific's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730817028_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In This Stock 15 Years Ago Would Be Worth $700 Today

Nuwellis, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUWE#NASDAQ">NUWE</a>) ("Nuwellis" or the "Company"), a commercial-stage medical device company committed to transforming the lives of people with fluid overload, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants issued by the Company on April 30, 2024 (collectively, the "Existing Warrants") to purchase up to an aggregate of 1,832,517 shares of the Company's common stock at their current exercise price of $2.10 per share for total gross proceeds of approximately $3.8 million, prior to deducting inducement agent fees and estimated offering expenses. An additional $1.3 million of gross proceeds was received through the exercise of warrants over the last week in accordance with their original terms.
Ladenburg Thalmann &amp; Co. Inc. acted as the exclusive warrant inducement agent for the exercise of the Existing Warrants.
In consideration for the immediate exercise of the Existing Warrants, the Company will issue Series I common stock purchase warrants (the "Series I Warrants") and Series II common stock purchase warrants (the "Series II Warrants") to purchase up to an aggregate of 3,665,034 shares of common stock. The Series I Warrants will have an exercise price of $1.94, will be exercisable six (6) months from the date of issuance, and will have a term of five (5) years from the date of exercisability. The Series II Warrants will have an exercise price of $1.94, will be exercisable six (6) months from the date of issuance, and will have a term of two (2) years from the date of exercisability. The Series I Warrants and Series II Warrants are fixed priced and do not contain any variable pricing features.
The Series I Warrants and Series II Warrants described above were offered in a private placement pursuant to an applicable exemption from the registration requirements under Section 4(a)(2) of the Securities Act of 1933 (the "Securities Act"), and, along with the shares of common stock issuable upon their exercise, have not been registered under the Securities Act, and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission (the "SEC") or an applicable exemption from such registration requirements.&nbsp; The securities were offered only to accredited investors. The Company has agreed to file a registration statement with the SEC covering the resale of the shares of common stock issuable upon exercise of the Series I Warrants and Series II Warrants.

Offerings

NUWE

Nuwellis Announces Exercise Of Warrants For $5.1M Of Gross Proceeds

Barclays analyst Brandt Montour maintains Wynn Resorts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WYNN#NASDAQ">WYNN</a>) with a Overweight and lowers the price target from $125 to $119.

WYNN

Barclays Maintains Overweight on Wynn Resorts, Lowers Price Target to $119

<ul>
<li>Tevogen Bio begins pre-clinical effort for TVGN 920, signaling the start of its oncology treatment pipeline.</li>
<li>Tevogen Bio created a data set containing known proteins in the HPV genome to identify targets, accelerating the pre-clinical process.</li>
<li>5.5 million women per year have HPV 16/18; of these 200,000 women per year are diagnosed with high grade dysplasia.</li>
</ul>
WARREN, N.J., Nov. 05, 2024 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=25EKK8KKg8fWa8WgKgjIJIFco_i1oqLlmbjUnyWXT5iNb9JBKkEdmsGmc5z909wZYXpUbPo70t3zgkjZ4RPLbA==">Tevogen Bio</a> ("Tevogen" or "Tevogen Bio Holdings Inc.") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVGN#NASDAQ">TVGN</a>), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, recently announced its Artificial Intelligence effort, Tevogen.AI, had partnered with Microsoft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), the world's leading AI company.
Using Microsoft's suite of advanced tools, Tevogen Bio is proactively investigating potential treatments for HPV to create a portfolio of oncology products. The company has developed a dataset of proteins from the HPV genome and is identifying cytotoxic T cell (CTL) targets to choose for a clinical trial for TVGN 920, its first oncology product. Through Tevogen's proprietary ExacTcell&#x2122; technology, where CTLs are trained to detect specific targets and then expanded, the company aims to be prepared to deliver an HPV-specific CTL treatment.

MSFT

TVGN

Tevogen Bio Leverages Microsoft Partnership To Deliver Machine Learning Based Target Identification To Address HPV, Advancing TVGN 920

Barclays analyst Julian Mitchell maintains Vontier (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VNT#NYSE">VNT</a>) with a Overweight and raises the price target from $44 to $46.

Barclays Maintains Overweight on Vontier, Raises Price Target to $46

The result of the combined effort of the two companies will be LiveWire's first electric maxi-scooter planned to launch in 1H 2026

LVWR

LiveWire & KYMCO Expand Partnership Resulting In First Electric Max-Scooter Planned To Launch In 1H 2026

Global

INTC

"Intel CEO Pat Gelsinger Paid A Brief Visit To Taiwan In Early November To Meet With TSMC Chairman C. C. Wei At The Hsinchu Science Park To Finalize 2nm And 3nm Production Capacity For 2024 And 2025, According To Industry Sources" - DigiTimes Alert

Barclays analyst Eddie Kim maintains Valaris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VAL#NYSE">VAL</a>) with a Overweight and lowers the price target from $61 to $59.

Barclays Maintains Overweight on Valaris, Lowers Price Target to $59

Rigel Resource Acquisition Corp (the "Company" or "Rigel") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RRAC#NYSE">RRAC</a>) announced that it received a notification letter from the New York Stock Exchange ("NYSE") on November 4, 2024, stating that it would suspend the listing of the Company's (i) Class A ordinary shares, par value $0.0001 per share (the "Class A Ordinary Shares"), (ii) warrants, each exercisable for one Class A Ordinary Share at an exercise price of $11.50 per share (the "Warrants") and (iii) units, each consisting of one Class A Ordinary Share and one-half of one Warrant (the "Units" and, collectively with the Class A Ordinary Shares and the Warrants, the "Securities") from the NYSE before market open on November 5, 2024 and commence delisting proceedings with respect to such Securities.
The NYSE determined to take these actions because Sections 102.06e and 802.01B of the NYSE's Listed Company Manual do not permit a special purpose acquisition company, such as the Company, to remain listed for more than three years after the company's initial public offering without completing an initial business combination.
Following the suspension of trading on the NYSE, the Securities are expected to trade on the OTC Pink Market.

RRAC

Rigel Resource Acquisition Corp Announces Receipt Of NYSE Delisting Notice, States That It Would Suspend The Listing Of The Co's Class A Ordinary Shares, Warrants, Each Exercisable For One Class A Ordinary Share At An Exercise Price Of $11.50 Per Share

- CRG-023 is a CD19-, CD20-, CD22-targeting tri-specific CAR T product candidate designed with the goal of providing more patients with a broad range of B-cell malignancies with durable responses by addressing several known causes of relapse, resulting in a potential best-in-class CAR T-cell therapy -
- First of its kind, tri-cistronic CAR T to express three independent CARs from a single vector, with each CAR having a distinct co-stimulatory domain –
- Data demonstrated sustained anti-tumor activity and a lack of functional exhaustion during repeated challenge from tumor cells, preservation of T cell memory phenotype relative to controls, sustained tumor clearance when only a single antigen is expressed, and robust in vivo, anti-lymphoma activity at low CAR T dose levels -
- Abstract will be presented during poster presentation at ASH, Saturday, December 7, 2024; 5:30 PM - 7:30 PM PST -

Events

CRGX

CARGO Therapeutics Announces ASH 2024 Abstract On CRG-023

Deutsche Bank analyst Carlo Santarelli maintains Wynn Resorts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WYNN#NASDAQ">WYNN</a>) with a Buy and lowers the price target from $122 to $118.

Deutsche Bank Maintains Buy on Wynn Resorts, Lowers Price Target to $118

Marriott International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAR#NASDAQ">MAR</a>) reported worse-than-expected third-quarter financial results and issued FY24 adjusted EPS guidance below <a href="https://www.benzinga.com/quote/MAR/earnings">estimates on Monday</a>.
The company reported a third-quarter adjusted EPS of $2.26, missing the street view of $2.31. Quarterly sales of $6.26 billion marginally missed the analyst consensus of $6.27 billion.
CEO Anthony Capuano highlighted Marriott&#8217;s strong quarter, noting solid net room and fee growth, active development, and a 3% rise in global RevPAR. He added that third-quarter international RevPAR increased by 5.4%, driven by substantial growth in APEC and EMEA regions, steady domestic and cross-border demand, and strong ADR gains.
Marriott expects fourth-quarter 2024 gross fee revenues to range between $1.29 billion and $1.31 billion, with adjusted EPS projected to be $2.31-$2.39, compared to a $2.31 estimate.
Marriott projects full-year 2024 adjusted EPS of $9.19-$9.27 (prior $9.23-$9.40), compared to the $9.36 estimate, with gross fee revenues of $5.126 billion-$5.146 billion (prior $5.13 billion-$5.18 billion).
Marriott shares fell 1.6% to close at $256.43 on Monday.
These analysts made changes to their price targets on Marriott following earnings announcement.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5967569b988ca8000127b8de/michael-bellisario">Baird analyst Michael Bellisario</a> maintained Marriott Intl with a Neutral and raised the price target from $258 to $264.</li>
<li>Barclays analyst Brandt Montour maintained the stock with an Equal-Weight and raised the price target from $240 to $249.</li>
</ul>
Considering buying MAR stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="544" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05092444/image-32-1024x544.png" alt="" class="wp-image-630414" style="width:646px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05092444/image-32-1024x544.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05092444/image-32-300x159.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05092444/image-32-768x408.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05092444/image-32.png 1217w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/news/24/11/41743859/top-3-consumer-stocks-that-may-keep-you-up-at-night-this-quarter">Top 3 Consumer Stocks That May Keep You Up At Night This Quarter</a></li>
</ul>

Earnings

Markets

Marriott Analysts Boost Their Forecasts After Q3 Earnings

Barclays analyst Raimo Lenschow maintains Teradata (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDC#NYSE">TDC</a>) with a Underweight and lowers the price target from $30 to $29.

Barclays Maintains Underweight on Teradata, Lowers Price Target to $29

Palantir Technologies Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>) shares are making new highs on Tuesday after the company reported strong quarterly results driven by <a href="https://www.benzinga.com/news/earnings/24/11/41730179/palantir-q3-earnings-revenue-beat-eps-beat-customers-up-39-raises-guidance-results-driven-by-unrele">&#8220;unrelenting&#8221; AI demand</a>. 
<ul>
<li>Q3 Revenue: $725.52 million, beating the&nbsp;<a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">consensus estimate</a>&nbsp;of $701.13 million</li>
</ul>
<ul>
<li>Q3 EPS: 6 cents, versus estimates of 4 cents</li>
</ul>
Palantir reported 30% year-over-year revenue growth in the quarter propelled by continued strength in the U.S. The company said U.S. revenue grew 44% year-over-year as U.S. Commercial revenue jumped 54% and U.S. Government revenue climbed 40% year-over-year.
The company beat analyst estimates on the top and bottom lines for the fifth consecutive quarter as margins expanded for the eighth straight quarter, and the company guided for continued GAAP operating income and net income in each quarter this year.
Customer count grew 39% year-over-year and 6% on a quarter-over-quarter basis. The company said it closed 104 deals worth over $1 million during the quarter.
&#8220;The growth of our business is accelerating, and our financial performance is exceeding expectations as we meet an unwavering demand for the most advanced artificial intelligence technologies from our U.S. government and commercial customers," Alex Karp, co-founder and CEO of Palantir, said in a letter to shareholders.
Check This Out: <a href="https://www.benzinga.com/news/24/11/41738657/palantir-ceo-alex-karp-warns-europe-risks-doom-without-ai">Palantir CEO Alex Karp Warns Europe Risks Doom Without AI</a>
Guidance: Palantir sees fourth-quarter revenue in the range of $767 million to $771 million, versus estimates of $741.44 million. The company also raised full-year guidance across its key metrics.
Palantir now expects full-year revenue in the range of $2.805 billion to $2.809 billion versus estimates of $2.759 billion, and full-year U.S. commercial revenue in excess of $687 million, representing growth of at least 50%. The company now expects adjusted free cash flow to be in excess of $1 billion for the year.
"We absolutely eviscerated this quarter, driven by unrelenting AI demand that won't slow down. This is a U.S.-driven AI revolution that has taken full hold. The world will be divided between AI haves and have-nots. At Palantir, we plan to power the winners,"&nbsp;Karp said.
Following the print, Wedbush analyst&nbsp;Dan Ives&nbsp;maintained an <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41732827/messi-of-ai-wall-street-analyst-gushes-over-robust-earnings-from-palantir">Outperform rating</a> on the stock noting that Palantir delivered &#8220;another robust quarter featuring beats across the board.&#8221;
"Despite the skeptics honing in on valuation for the past year, this was a major quarter to prove that PLTR&#8217;s partner ecosystem expansion and AIP bootcamps hit another gear," Ives said.
PLTR Price Action: <a href="https://www.benzinga.com/quote/PLTR" target="_blank" rel="noreferrer noopener">Palantir shares </a>were up 15.7% at $47.93 at the time of publication Tuesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/11/41734887/cathie-woods-latest-shake-up-dumps-palantir-and-jack-dorseys-block-along-with-tesla-buys-amazon-">Cathie Wood&#8217;s Latest Shake-up: Dumps Palantir And Jack Dorsey&#8217;s Block Along With Tesla, Buys Amazon And Meta</a></li>
</ul>
Photo: <a href="https://www.flickr.com/photos/doctorow/" target="_blank" rel="noreferrer noopener">Cory Doctorow</a>&nbsp;from Flickr.

Movers

PLTR

Palantir Stock Is Hitting New Highs: What's Going On?

Barclays analyst Nicholas Campanella maintains Public Service Enterprise (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEG#NYSE">PEG</a>) with a Overweight and lowers the price target from $98 to $88.

Barclays Maintains Overweight on Public Service Enterprise, Lowers Price Target to $88

Vaccinex stock plunges 24% on mixed results for Alzheimer's study

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
It&rsquo;s time to start off the final trading day of the week with a breakdown of the biggest pre-market stock movers for Friday morning!



Moving stocks this morning are earnings reports, a failed merger deal, delisting updates and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>VSee Health (NASDAQ:<a href="https://investorplace.com/stock-quotes/vsee-stock-quote/">VSEE</a>) stock is rocketing more than 159% as the robot maker <a href="https://www.nasdaq.com/press-release/vsee-health-and-ava-robotics-partner-develop-telepresence-solutions-hospital">plans for telepresence solutions</a> for the inpatient intensive care market.</li>



<li>Adagio Medical (NASDAQ:<a href="https://investorplace.com/stock-quotes/adgm-stock-quote/">ADGM</a>) shares are soaring close to 36% following its <a href="https://www.businesswire.com/news/home/20240731222906/en/Adagio-Medical-Announces-the-Closing-of-the-Business-Combination-with-ARYA-IV-Creating-a-Publicly-Traded-Company-Focused-on-the-Innovative-Technologies-for-Treatment-of-Cardiac-Arrhythmias">recent public debut</a>.</li>



<li>Akanda (NASDAQ:<a href="https://investorplace.com/stock-quotes/akan-stock-quote/">AKAN</a>) stock is surging over 35% alongside heavy pre-market trading.</li>



<li>Exicure (NASDAQ:<a href="https://investorplace.com/stock-quotes/xcur-stock-quote/">XCUR</a>) shares are gaining more than 29% on a <a href="https://www.businesswire.com/news/home/20240801299565/en/Exicure-Inc.-Receives-Positive-Listing-Determination-from-Nasdaq">positive listing update</a> from the Nasdaq Capital Market.</li>



<li>Australian Oilseeds (NASDAQ:<a href="https://investorplace.com/stock-quotes/coot-stock-quote/">COOT</a>) stock is rising 25% after announcing a <a href="https://www.nasdaq.com/press-release/australian-oilseeds-announces-appointment-new-independent-auditor-2024-08-01">new independent auditor</a>.</li>



<li>Tandem Diabetes Care (NASDAQ:<a href="https://investorplace.com/stock-quotes/tndm-stock-quote/">TNDM</a>) shares are increasing nearly 25% with the release of its <a href="https://www.nasdaq.com/press-release/tandem-diabetes-care-announces-second-quarter-2024-financial-results-and-increases">Q2 earnings report</a>.</li>



<li>Vaccinex (NASDAQ:<a href="https://investorplace.com/stock-quotes/vcnx-stock-quote/">VCNX</a>) stock is heading over 23% higher with <a href="https://www.nasdaq.com/press-release/vaccinex-reports-positive-data-signal-ad-phase-1b-2-trial-pepinemab-alzheimers">recent clinical trial news</a>.</li>



<li>AGBA Group (NASDAQ:<a href="https://investorplace.com/stock-quotes/agba-stock-quote/">AGBA</a>) shares are climbing more than 13% without any clear news this morning.</li>



<li>Venus Concept (NASDAQ:<a href="https://investorplace.com/stock-quotes/vero-stock-quote/">VERO</a>) stock is jumping over 13% on Friday morning.</li>



<li>Integral Ad Science (NASDAQ:<a href="https://investorplace.com/stock-quotes/ias-stock-quote/">IAS</a>) shares are up 13% with its <a href="https://www.nasdaq.com/press-release/ias-reports-second-quarter-2024-financial-results-2024-08-01">latest earnings news</a>.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Gamer Pakistan (NASDAQ:<a href="https://investorplace.com/stock-quotes/gpak-stock-quote/">GPAK</a>) stock is plummeting almost 47% <a href="https://www.pr.com/press-release/917157#:~:text=(Nasdaq%3AGPAK)%20(GPAK,and%20that%20trading%20of%20the">alongside a delisting notice</a>.</li>



<li>Fresh Vine Wine (NYSEMKT:<a href="https://investorplace.com/stock-quotes/vine-stock-quote/">VINE</a>) shares are diving more than 37% with the <a href="https://www.nasdaq.com/press-release/fresh-vine-wine-inc-and-notes-live-inc-mutually-agree-terminate-merger-agreement-2024">termination of a merger agreement</a>.</li>



<li>Conn&rsquo;s (NASDAQ:<a href="https://investorplace.com/stock-quotes/conn-stock-quote/">CONN</a>) stock is tumbling over 30% as Badcock Home Furniture &amp; More <a href="https://nypost.com/2024/08/01/business/major-furniture-chain-badcock-to-shut-all-its-stores-after-120-years/">shuts down all of its stores</a>.</li>



<li>Greenlane (NASDAQ:<a href="https://investorplace.com/stock-quotes/gnln-stock-quote/">GNLN</a>) shares are taking a more than 24% beating on plans for a <a href="https://www.stocktitan.net/news/GNLN/greenlane-announces-board-s-approval-of-reverse-stock-split-9yehmvs5r4ed.html">reverse stock split</a>.</li>



<li>Procore Technologies (NYSE:<a href="https://investorplace.com/stock-quotes/pcor-stock-quote/">PCOR</a>) stock is dropping 22% alongside its <a href="https://www.nasdaq.com/press-release/procore-announces-second-quarter-2024-financial-results-2024-08-01">Q2 earnings report</a>.</li>



<li>Estrella Immunopharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/esla-stock-quote/">ESLA</a>) shares are sliding close to 21% on Friday morning.</li>



<li>Intel (NASDAQ:<a href="https://investorplace.com/stock-quotes/intc-stock-quote/">INTC</a>) stock is falling over 20% after releasing its <a href="https://www.theverge.com/2024/8/1/24210656/intel-is-laying-off-over-10000-employees-and-will-cut-10-billion-in-costs">Q2 earnings report</a>.</li>



<li>Smith Micro Software (NASDAQ:<a href="https://investorplace.com/stock-quotes/smsi-stock-quote/">SMSI</a>) shares are decreasing more than 19% with its <a href="https://seekingalpha.com/article/4709513-smith-micro-software-inc-smsi-q2-2024-earnings-call-transcript">latest earnings report</a>.</li>



<li>GraniteShares 2x Long AMZN Daily ETF (NASDAQ:<a href="https://investorplace.com/stock-quotes/amzz-stock-quote/">AMZZ</a>) stock is slipping over 17%.</li>



<li>Snap (NYSE:<a href="https://investorplace.com/stock-quotes/snap-stock-quote/">SNAP</a>) shares close out our pre-market stock movers down more than 17% <a href="https://www.cnbc.com/2024/08/01/snap-shares-plunge-over-20percent-af.html">on weak guidance</a>.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/2024/08/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-friday-aug-2nd/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

The latest announcement is out from Vaccinex (VCNX). Vaccinex, Inc. has announced new insights from its SIGNAL-AD Phase 1b/2 trial assessing the pe...

Vaccinex Provides Update on Alzheimer's Treatment Trial

Vaccinex says Alzheimer's candidate buoyed by additional early-stage data

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Vaccinex (NASDAQ:<a href="https://investorplace.com/stock-quotes/vcnx-stock-quote/">VCNX</a>) just reported results for the second quarter of 2024.<ul><li>Vaccinex reported earnings per share of -$3.10.</li><li>The company reported revenue of $232,000.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/vcnx-stock-earnings-vaccinex-for-q2-of-2024/">VCNX Stock Earnings: Vaccinex Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

VCNX Stock Earnings: Vaccinex Reported Results for Q2 2024

An announcement from Vaccinex ( ($VCNX) ) is now available. Chrystyna Bedrij Stecyk has abruptly resigned as a director of Vaccinex, Inc., effectiv...

Vaccinex Director Chrystyna Bedrij Stecyk Abruptly Resigns

Vaccinex exercises warrants for proceeds of $6.2M

Vaccinex files for secondary stock offering

Vaccinex (VCNX) announced that it will present promising new efficacy and safety data for its randomized, double-blind, phase 1b/2 SIGNAL-AD study ...

Vaccinex announces it will present new data for Phase 1b/2 SIGNAL-AD study

Vaccinex (VCNX) provided an update on new clinical findings from its SIGNAL-AD Phase 1b/2 trial of pepinemab antibody in Alzheimer's disease. Vacci...

Vaccinex reports new findings from SIGNAL-AD Phase 1b/2 trial of pepinemab

ADGM

AGBA

AKAN

AMZZ

BIIB

CONN

COOT

ESAIY

ESALF

ESLA

GNLN

GPAK

PCOR

SMSI

SNAP

TNDM

VCNX

VERO

VINE

VSEE

XCUR

Press Releases

Vaccinex Reports 2023 Financial Results and Provides Corporate Update

Financing

Vaccinex Reports First Quarter 2024 Financial Results and Provides Corporate Update

Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer's Disease

Vaccinex to report topline data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer's Disease at the Alzheimer's Association International Conference, Philadelphia, July 31, 2024

Vaccinex Reports Positive Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer's Disease

Health Care

Vaccinex Provides Update on New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab in Alzheimer's Disease and Plans to Pursue a Development Partnership

Vaccinex Announces Exercise of Warrants for $6.2 Million in Gross Proceeds

Vaccinex to Report Promising New Efficacy Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab at Clinical Trials on Alzheimer's Disease (CTAD) Conference on October 31, 2024

Vaccinex Reports New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab at Clinical Trials on Alzheimer's Disease (CTAD) Conference in Madrid, Spain

Vaccinex Reports Improved Immunity Correlating with Clinical Benefit of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer's Annual Meeting

Comments

Vaccinex

Notizie

Ultime notizie per Vaccinex (NASDAQ:VCNX) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO